LYEL · NASDAQ · Biotechnology

Lyell Immunopharma (LYEL)

Develops CAR T-cell candidates for lymphoma and metastatic colorectal cancer.

$15.10
Pre-market+0.14 (+0.94%)
At close$14.96(+2.96%)

Something off on this page? Send us feedback.

Next report
Nov 10, 2026
estimated · in 68 days
EPS estimate
−$2.06
Revenue estimate
$3.8K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.72−$3.60−$2.89−$2.13−$7.68−$1.10−$1.92Pending
Estimate−$0.18−$3.80−$3.80−$2.81−$2.15−$2.78−$1.90−$2.06
Surprise−300.0%+5.3%+23.9%+24.2%−257.2%+60.4%−1.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$11.0K$7.0K$8.0K$15.0K$6.0K$2.0K$4.0KPending
Estimate$4.0K$15.3K$3.0K$3.6K$3.8K
Surprise+100.0%−60.7%−33.3%+10.3%

History

DateEstimateReportedSurprise
Nov 2026−$2.06
Aug 2026−$1.90−$1.92−1.1%
May 2026−$2.78−$1.10+60.4%
Mar 2026−$2.15−$7.68−257.2%
Nov 2025−$2.81−$2.13+24.2%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
Jun 2021
Mar 2021
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 10, 2026−$2.06$3.8K
Aug 6, 2026−$1.90−$1.92−1.1%$3.6K$4.0K+10.3%+3.5%
May 6, 2026−$2.78−$1.10+60.4%$3.0K$2.0K−33.3%−3.8%
Mar 12, 2026−$2.15−$7.68−257.2%$15.3K$6.0K−60.7%−14.3%
Nov 12, 2025−$2.81−$2.13+24.2%$15.0K−1.3%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 13, 2025
Mar 11, 2025
Nov 7, 2024
Aug 7, 2024
May 6, 2024
Feb 28, 2024
Nov 7, 2023
Aug 8, 2023
May 4, 2023
Feb 28, 2023
Nov 8, 2022
Aug 4, 2022
May 10, 2022
Mar 29, 2022
Nov 12, 2021
Aug 12, 2021
Jun 18, 2021
Mar 31, 2021
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020